Lancet

Publication date: 2000-01-01
Volume: 355 Pages: 337 - 345
Publisher: Lancet ltd

Author:

Topol, CE
Califf, RM ; Simes, RJ ; Van de Werf, Frans ; Diaz, R ; Paolasso, E ; Aylward, PE ; Keech, A ; Klein, W ; Piegas, L ; Tomov, I ; Armstrong, PW ; Widimsky, P ; Grande, P ; Halinen, M ; Vahanian, A ; Neuhaus, K ; Dimas, AP ; Preda, I ; Kristinsson, A ; Tzivoni, D ; Ardissino, D ; White, HD ; Madsen, S ; Sugrue, D ; Sadowski, Z ; Seabra-Gomes, R ; Apetrei, E ; Dalby, A ; Betriu, A ; Pfisterer, M ; Verheugt, F ; Fox, K ; Bates, ER ; Gibler, WB ; Granger, CB ; Harrington, RA ; Hochman, JS ; Holmes, DR ; Kleiman, NS ; Lee, KL ; Moliterno, DJ ; Newby, LK ; Ohman, EM ; Califf, R ; Newby, K ; Zillman, L ; Lee, K ; Lemons, P ; McCourt, B ; Campbell, C ; Tardiff, B ; Snapp, J ; Bassett, K ; Hodgson, P ; Hannan, K ; Kandzari, L ; Hawkins, S ; Hinman-Smith, E ; McDougal, M ; Raffetto, K ; Thompson, D ; Wehrle, T ; Ange, C ; Brown, R ; Grissom, G ; Heuckel, M ; McCall, J ; Pennachi, W ; Spychala, M ; Veasey, S ; Pullium, M ; Journey, T ; Quintero, K ; Mark, D ; Davidson-Ray, L ; Diner, L ; Nelson, C ; Sowers, C ; Webb, G ; Young, M ; Bhapkar, M ; Pacchiana, C ; Sparapani, R ; Tuttle, R ; Weaver, D ; Borzak, S ; Douthat, L ; Topol, E ; Moliterno, D ; Konczos, L ; Baishnab, R ; Baishnab, R ; Bakos, A ; Blashford, L ; Bratsch, J ; Brown, K ; Cadorini, E ; Carlson, J ; Clemmons, P ; DelValle, M ; Drabik, M ; Fu, G ; Gates, K ; Gibson, Y ; Heil, L ; Hill, N ; Klancar, R ; McHale, B ; Montague, E ; Pasca, N ; Pergi, L ; Randall, R ; Rosso, R ; Sankovich, K ; Smith, D ; Wisniewski, L ; Witkowski, M ; Zovkic, V ; Alexander, K ; Bhatt, D ; Brener, S ; Campbell, L ; Cho, L ; Cole, C ; Deedy, M ; Foody, J ; Gassler, J ; Ghaffari, S ; Haas, G ; Kapadia, S ; Lauer, M ; Lauer, MS ; Lincoff, M ; Lutton, S ; Marso, S ; Mukherjee, D ; Patel, V ; Penn, M ; Robbins, M ; Roe, M ; Sila, C ; Thamilarasan, M ; Wagner, G ; Armstrong, P ; Bestilny, S ; Van de Werf, Frans ; Budts, Werner ; Graux, S ; Luyten, Anne ; Simes, J ; Keech, A ; Kava, M ; Bower, T ; Chan, S ; Crampton, L ; Monro, C ; Nayak, M ; Parente, G ; Riley, V ; Wilton, D ; Aylward, P ; Dolan, S ; Thomas, C ; White, H ; Scott, M ; Frye, R ; Alpert, J ; Bertrand, M ; Ryan, T ; Fisher, L ; Asarch, L ; Smith, M ; Lim, L ; Bokslag, M ; Chiu, P ; Chung, J ; Collins, S ; Dougherty, C ; Guimaraes, D ; Hakim, Z ; Mathieson, J ; Montgomery, L ; Novotny, B ; Steiner, B ; Wittke, B

Keywords:

platelet, inhibitors, blockade, disease, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, PLATELET, INHIBITORS, BLOCKADE, DISEASE, Administration, Oral, Aged, Angina, Unstable, Aspirin, Double-Blind Method, Female, Humans, Male, Middle Aged, Odds Ratio, Oximes, Piperidines, Platelet Aggregation Inhibitors, Platelet Glycoprotein GPIIb-IIIa Complex, Recurrence, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Background Aspirin lowers risks of death and myocardial infarction in patients with acute coronary syndromes. Intravenous glycoprotein IIIb/IIIa receptor antagonists further reduce the rates of ischaemic events in these patients, but the efficacy of long-term oral glycoprotein IIb/IIIa receptor blockade has not been established. We tested whether the oral glycoprotein IIb/IIIa receptor antagonist sibrafiban would prevent more cardiovascular events than aspirin, when given within 7 days of, and sustained for 90 days after, an acute coronary syndrome event.